Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer.

Autor: El-Ghobashy NM; Department of Medicinal Chemistry Pharmacy, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt., El-Sayed SM; Department of Medicinal Chemistry Pharmacy, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. salwanmahmoud@mans.edu.eg., Shehata IA; Department of Medicinal Chemistry Pharmacy, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt., El-Ashmawy MB; Department of Medicinal Chemistry Pharmacy, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Sep 28; Vol. 12 (1), pp. 16246. Date of Electronic Publication: 2022 Sep 28.
DOI: 10.1038/s41598-022-20260-1
Abstrakt: Many benzoxazole-based and similar scaffolds were reported to have wide-range of anticancer activities. In this study, four series of benzoxazole derivatives were designed by combining benzoxazole scaffold with different amines via a reversed phenyl amide linker to produce the compounds of series A, B and C. A fourth new hybrid of benzoxazole with 1,2,3 triazole ring (series D) was also designed. The designed compounds were synthesized and screened for their anti-breast cancer activity against MDA-MB-231 and MCF-7 cell lines using MTT assay. The most potent cytotoxic compounds; 11-14, 21, 22, 25-27 were further evaluated for their in vitro PARP-2 enzyme inhibition. Compounds 12 and 27 proved to be the most active PARP-2 inhibitors with IC 50 values of 0.07 and 0.057 µM, respectively. Compounds 12 and 27 caused cell cycle arrest in mutant MCF-7 cell line at G2/M and G1/S phase, respectively and they possessed significant apoptosis-promoting activity. Docking results of compounds 12 and 27 into PARP-2 pocket demonstrated binding interactions comparable to those of olaparib. Their predicted pharmacokinetic parameters and oral bioavailability appeared to be appropriate. Collectively, it could be concluded that compounds 12 and 27 are promising anti-breast cancer agents that act as PARP-2 inhibitors with potent apoptotic activity.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje